Patent · US Expired

Methods utilizing mutant rev genes encoding transdominant repressors of HIV replication

US6251675A · kind A · utility

0Cited by
4References
49Claims
0Family size

Assignee

Inventor

Key dates

Filing dateJun 2, 1995
Grant dateJun 26, 2001
Priority date
Expiry dateJun 2, 2015

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2740/16322
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Transdominant repressors of viral gene phenotypic expression derived from the rev gene product of HIV-1 or the rex gene product of HTLV-1 and corresponding mutated genes are described, having the capability of repressing the Rev function in HIV-1 and/or the Rex function in HTLV-I and HTLV-II. Transient gene expression analysis of a series of missense and deletion mutants has been used. Sane of the mutants found repress both the Rev and the Rex function and are thus active in more than one viral species. Transdominant viral mutants represent a promising new class of anti-viral agents. Cellular expression of these transdominant inhibitors may be used in such therapeutic approaches as intracellular immunization in order to protect cells against the deleterious effects of viral, e.g. HIV-1 infection.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.